A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches
botulinum toxin type A; episodic migraine; prophylaxis
Abstract :
[en] Our aim was to evaluate the safety and efficacy of botulinum toxin type A (BoNTA; BOTOX (R)) for prophylaxis of episodic migraine. In this double-blind, placebo-controlled study, patients were randomized to 225, 150 or 75 U of BoNTA or placebo after a 30-day placebo run-in for three 90-day treatment cycles. The primary efficacy end-point was the mean reduction from baseline in the frequency of migraine episodes at day 180 in the placebo non-responder stratum. All groups (N = 495) improved, with no significant differences. At day 180, the frequency of migraine episodes was reduced from baseline means of 4.3, 4.7, 4.7 and 4.4 by 1.6, 1.7, 1.5 and 1.4 for BoNTA 225 U, 150 U and 75 U and placebo, respectively. The primary end-point was not met. Treatment-related adverse events were transient and mild to moderate. BoNTA treatment was safe and well tolerated but did not result in significantly greater improvement than placebo in this study. Several factors may have confounded the results.
Disciplines :
Neurosciences & behavior Neurology
Author, co-author :
Relja, M.
Poole, A. C.
Schoenen, Jean ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Neuro-anatomie
Pascual, J.
Lei, X.
Thompson, C.
Language :
English
Title :
A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches
Silberstein SD, Neto W, Schmitt J, Jacobs D. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004 61 : 490 5.
Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001 41 : 646 57.
Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States: epidemiology and patterns of health care use. Neurology 2002 58 : 885 94.
Badia X, Magaz S, Gutierrez L, Galvan J. The burden of migraine in Spain: beyond direct costs. Pharmacoeconomics 2004 22 : 591 603.
Leonardi M, Steiner TJ, Scher AT, Lipton RB. The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF). J Headache Pain 2005 6 : 429 40.
Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999 159 : 813 8.
Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart WF. Migraine, quality of life, and depression: a population-based case-control study. Neurology 2000 55 : 629 35.
Lipton RB, Liberman JN, Kolodner KB, Bigal ME, Dowson A, Stewart WF. Migraine headache disability and health-related quality-of-life: a population-based case-control study from England. Cephalalgia 2003 23 : 441 50.
Ferrari MD. The economic burden of migraine to society. Pharmacoeconomics 1998 13 : 667 76.
Bigal ME, Rapoport AM, Bordini CA, Tepper SJ, Sheftell FD, Speciali JG. Burden of migraine in Brazil: estimate of cost of migraine to the public health system and an analytical study of the cost-effectiveness of a stratified model of care. Headache 2003 43 : 742 54.
Pradalier A, Auray JP, El Hasnaoui A, Alzahouri K, Dartigues JF, Duru G et al. Economic impact of migraine and other episodic headaches in France: data from the GRIM2000 study. Pharmacoeconomics 2004 22 : 985 99.
Silberstein SD. Migraine: preventive treatment. Curr Med Res Opin 2001 17 : s87 s93.
Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N Engl J Med 2002 346 : 257 70.
Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004 291 : 965 73.
Gallagher RM, Kunkel R. Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache 2003 43 : 36 43.
Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache 2003 43 : S16 S24.
Naumann M, Yakovleff A, Durif F for the BOTOX® Cervical Dystonia Prospective Study Group. A randomized, double-masked crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. J Neurol 2002 249 : 57 63.
Brashear A, Gordon M, Elovic E, Kassicieh VD, Marciniak C, Do M et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002 347 : 395 400.
Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003 43 : 9 15.
Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004 107 : 125 33.
Durham PL, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004 44 : 35 43.
Lang AM. Botulinum toxin type A therapy in chronic pain disorders. Arch Phys Med Rehabil 2003 84 : S69 S73.
Dodick DW. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: from bench to bedside. Headache 2003 43 : S25 S33.
Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C and the BOTOX CDH Study Group. Botulinum toxin type A (BOTOX®) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 2005 45 : 293 307.
Silberstein SD, Stark SR, Lucas SM, Christie SN, DeGryse RE, Turkel CC BoNTA-039 Study Group. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005 80 : 1126 37.
Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD, and the BOTOX Study Group. Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 2005 45 : 315 24.
Silberstein S, Mathew N, Saper J, Jenkins S, Group for the BOTOX Migraine Clinical Research Group. Botulinum toxin type A as a migraine preventive treatment. Headache 2000 40 : 445 50.
Evers S, Vollmer-Haase J, Schwaag S, Rahmann A, Husstedt I-W, Frese A. Botulinum toxin A in the prophylactic treatment of migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2004 24 : 838 43.
Aurora S, Gawel M, Brandes J, Pokta S, VanDenburgh A. Botulinum toxin type A prophylactic treatment of episodic migraine using a modified follow-the-pain treatment paradigm: a randomized, double-blind, placebo-controlled Phase II study. Headache 2005 45 : 826 7 [Abstract].
Elkind AH, O'Carroll CP, Blumenfeld A, DeGryse R, Dimitrova R. A randomized, controlled, 3 study series of multiple treatments with low doses of botulinum toxin type A for the prophylaxis of episodic migraine. J Neurol 2005 252 (Suppl. 2 ii51 ii95 [Abstract].
Blumenfeld AM, Binder W, Silberstein SD, Blitzer A. Procedures for administering botulinum toxin type A for migraine and tension-type headache. Headache 2003 43 : 884 91.
O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979 35 : 549 56.
Siegel S. Nonparametric statistics for the behavioral sciences. New York : McGraw-Hill Co. 1956 : 116 27.
Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001 41 : 119 28.
Freitag FG, Collins SD, Carlson HA, Goldstein J, Saper J, Silberstein S et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002 58 : 1652 9.
Couch JR Jr. Placebo effect and clinical trials in migraine therapy. Neuroepidemiology 1987 6 : 178 85.
Bendtsen L, Mattsson P, Zwart JA, Lipton RB. Placebo response in clinical randomized trials of analgesics in migraine. Cephalalgia 2003 23 : 487 90.
Loder E, Goldstein R, Biondi D. Placebo effects in oral triptan trials: the scientific and ethical rationale for continued use of placebo controls. Cephalalgia 2005 25 : 124 31.
Colloca L, Benedetti F, Pollo A. Repeatability of autonomic responses to pain anticipation and pain stimulation. Eur J Pain 2006 10 : 659 65.
Finniss DG, Benedetti F. Mechanisms of the placebo response and their impact on clinical trials and clinical practice. Pain 2005 114 : 3 6.
Zubieta JK, Bueller JA, Jackson LR, Scott DJ, Xu Y, Koeppe RA et al. Placebo effects mediated by endogenous opioid activity on mu-opioid receptors. J Neurosci 2005 25 : 7754 62.
Zubieta JK, Yau WY, Scott DJ, Stohler CS. Belief or need? Accounting for individual variations in the neurochemistry of the placebo effect. Brain Behav Immun 2006 20 : 15 26.
Linde M, May A, Limmroth V, Dahlof C Headache Masters Programme. Ethical aspects of placebo in migraine research. Cephalalgia 2003 23 : 491 5.
